Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria.
J Infect Dis
; 187(7): 1137-41, 2003 Apr 01.
Article
em En
| MEDLINE
| ID: mdl-12660928
ABSTRACT
The relationship between the efficacy of amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria and preexisting antibodies against merozoite surface protein (MSP)-1, a blood-stage P. falciparum antigen, was investigated. The immunoglobulin G antibody response to different MSP-1 recombinant proteins was evaluated in plasma samples from Gabonese children with uncomplicated malaria who were treated with amodiaquine. The prevalence of anti-MSP-1 antibodies was similar among patients with either parasitological and clinical cure after treatment (n=102) or treatment failure (n=51) by day 28 (83% in both groups). However, associations between antibody responses to K1 and MAD20 allelic families and therapeutic success were found (P< .001 and P= .034, respectively). A high proportion of plasma samples recognizing several antigens was found in the cured group. This association was significant even when data were stratified by age, particularly for the K1 family antigens (P= .029). These results suggest that humoral immune responses play a supportive role in the efficacy of amodiaquine treatment.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Plasmodium falciparum
/
Anticorpos Antiprotozoários
/
Malária Falciparum
/
Proteína 1 de Superfície de Merozoito
/
Amodiaquina
/
Antimaláricos
Tipo de estudo:
Risk_factors_studies
Limite:
Animals
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
País como assunto:
Africa
Idioma:
En
Ano de publicação:
2003
Tipo de documento:
Article